WO1990000902A1 - Monoclonal antibodies reactive with cachectin - Google Patents

Monoclonal antibodies reactive with cachectin Download PDF

Info

Publication number
WO1990000902A1
WO1990000902A1 PCT/US1989/003025 US8903025W WO9000902A1 WO 1990000902 A1 WO1990000902 A1 WO 1990000902A1 US 8903025 W US8903025 W US 8903025W WO 9000902 A1 WO9000902 A1 WO 9000902A1
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibody
cachectin
monoclonal antibodies
human
antibodies
Prior art date
Application number
PCT/US1989/003025
Other languages
French (fr)
Inventor
George Kuo
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Publication of WO1990000902A1 publication Critical patent/WO1990000902A1/en
Priority to FI901344A priority Critical patent/FI101937B/en
Priority to NO901247A priority patent/NO179615C/en
Priority to DK069890A priority patent/DK69890A/en
Priority to NO952509A priority patent/NO180637C/en
Priority to FI954230A priority patent/FI102115B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the present invention relates to the application of immunological techniques to provide novel materials useful in diagnosing and treating, inter alia, bacterial infection, and, more particularly, to the production and application of improved monoclonal antibodies that are capable of specifically reacting with human cachectin.
  • invasive stimuli such as parasitic, bacterial or viral infections, or neoplastic cells
  • invasive stimuli induce significant metabolic changes in the susceptible host. If serious, the changes may eventually disrupt normal homeostatic mechanisms, both locally and systemically, leading to the depletion of host energy stores advancing to wasting (Cachexia) , tissue damage, multiple organ system failure, shock and death.
  • Cachexia wasting
  • tissue damage a fibroblast damage
  • multiple organ system failure multiple organ system failure
  • shock and death Until recently, clinicians believe that the systematic patterns were primarily due to actions of the invasive agents themselves.
  • the invasive stimuli caused the host to generate various cytokines, the combined actions of which cause most of the undesirable biological responses.
  • These host-derived inflammatory mediators present new opportunities for developing treatment regimens against a wide variety of inflammatory disease states.
  • Cachectin also known as Tumor Necrosis Factor, is a protein having 157 amino acids normally found in vivo as a dimer or other multimer. The calculated molecular weight of human TNF monomer is about 17,000 daltons.
  • Cachectin acts to suppress biosynthesis of several adipocyte-specific proteins, such as lipoprotein lipase. It also acts to induce the biosynthesis or release of numerous other proteins, including Class I major histocompatibility antigen, granulocyte- acrophage-colony stimulating factor, and interleukin 1. (See, generally, Beutler and Cerami, New Eng. J. of Med., 3l6;379-385 (1987), which is incorporated herein by reference.)
  • Novel cell lines are provided which produce monoclonal antibodies capable of binding to human cachectin epitopes with enhanced neutralization capability in vivo. Additionally, methods are provided for treating a human susceptible to bactere ia or sepsis or already infected with an endotoxin-bearing bacteria by administering a prophylactic or therapeutic amount of a composition comprising at least .one monoclonal antibody or binding fragment thereof capable of reacting with human cachectin and exhibiting neutralizing activity in an L929 cell cytolytic assay at less than about 400ng, typically between about 50 to 200 ng or more, the composition preferably further including a physiologically acceptable carrier.
  • the composition may also contain any one or more of the following: additional monoclonal antibodies capable of reacting with bacterial endotoxins or exotoxins; monoclonal antibodies capable of reacting with serotype determinants on particular bacterial strains bearing endotoxins; a gamma globulin fraction from human blood plasma; a gamma globulin fraction from human blood plasma, where the plasma may be obtained from a human exhibiting elevated levels of immunoglobulins reactive with bacterial endotoxins; and one or more antimicrobial agents. Further, clinical uses of the monoclonal antibodies are provided, including the production of diagnostic kits.
  • novel cells capable of producing neutralizing monoclonal antibodies of desired affinities and compositions comprising such antibodies are provided, such compositions being capable of selectively recognizing epitopes present on human cachectin.
  • the subject cells have identifiable chromosomes in which the germ-line DNA from them or a precursor cell has rearranged to encode an antibody having a binding site for a desired epitope on human cachectin.
  • These monoclonal antibodies can be used in a wide variety of ways, including diagnosis and therapy.
  • the monoclonal antibodies so provided are particularly useful, when compared to prior art antibodies, in the treatment or prophylaxis of serious diseases, such as bacteremia, sepsis, cachexia, or other disease states associated with elevated levels of cachectin.
  • the antibodies will typically have neutralizing activity at less than 400 ng, perferably less than about 300 ng, most preferably about 50 to 200 ng, in the L929 cell cytolytic assay. This higher level of activity permits utilizing significantly lower dosage levels for treatments.
  • the preparation of monoclonal antibodies can be accomplished by immortalizing a cell line capable of expressing nucleic acid sequences that code for antibodies specific for an appropriate epitope on human cachectin.
  • the immortalized cell line may be a mammalian cell line that has been transformed through oncogenesis, by transfection, mutation, or the like.
  • Such cells include myeloma lines, lymphoma lines, or other cell line capable of supporting the expression and secretion of the immunoglobulin, or binding fragment thereof, in vitro.
  • the immunoglobulin or fragment may be a naturally-occurring immunoglobulin of a mammal other than the preferred mouse or human sources, produced by transformation of a lymphocyte, particularly a splenocyte, by means of a virus or by fusion of the lymphocyte with a neoplastic cell, e.g., a myeloma, to produce a hybrid cell line.
  • the splenocyte will be obtained from an animal immunized against cachectin-related antigens or fragments thereof containing an epitopic site. Immunization protocols are well known and can vary considerably yet remain effective. (See, Goding, Monoclonal Antibodies: Principles and
  • hybrid cell lines may be cloned and screened in accordance with conventional techniques, and antibodies in the cell supernatants detected that are capable of binding to the desired human cachectin determinants with appropriate affinities.
  • the appropriate hybrid cell lines may then be grown in large-scale culture or injected into the peritoneal cavity of an appropriate host for production of antibodies ascites fluid.
  • the supernatants of subsequent experiments may be screened in a competition assay with the subject monoclonal antibodies as a means to identify additional examples of the desired anti-human cachectin monoclonal antibodies (so-called "blocking antibodies”) .
  • blocking antibodies anti-human cachectin monoclonal antibodies
  • hybrid cell lines are available that produce antibodies specific for the subject epitopic sites
  • these hybrid cell lines may be fused with other neoplastic B-cells, where such other B-cells may serve as recipients for genomic DNA coding for the antibodies.
  • These antibodies may be functional at the cell surface and not, for example, as receptors. While rodent, particularly murine, neoplastic B-cells are most commonly utilized, other mammalian species may be employed, such as lagomorpha, bovine, ovine, equine, porcine, avian or the like.
  • the monoclonal antibodies may be of any of the classes or subclasses of immunoglobulins, such as IgM, IgD, IgA, IgE, or subclasses of IgG known for each species of animal. Generally, the monoclonal antibodies may be used intact, or as binding fragments, such as Fv, Fab, F(ab') 2 , but usually intact.
  • the cell lines of the present invention may find use other than for the direct production of the monoclonal antibodies.
  • the cell lines may be fused with other cells
  • the cell lines may be used as a source of the chromosomes encoding the immunoglobulins, which may be isolated and transferred to cells by techniques other than fusion.
  • the genes encoding the monoclonal antibodies may be isolated and used in accordance with recombinant DNA techniques for the production of the specific immunoglobulin in a variety of hosts.
  • a single cDNA clone, coding for the immunoglobulin and free of introns may be isolated and placed into suitable prokaryotic or eukaryotic expression vectors and subsequently transformed into a host for ultimate bulk production.
  • suitable prokaryotic or eukaryotic expression vectors See, generally, U. S. Nos. 4,172,124; 4,350,683; 4,363,799; 4,381,292; and 4,423,147.
  • the immunoglobulins or fragments of the present invention may be produced in bacteria or yeast. (See, Boss, et al., Nucl. Acid.
  • the messenger RNA transcribed from the genes coding for the light and heavy chains of the monoclonal antibodies produced by a cell line of the present invention may be isolated by differential cDNA hybridization employing cDNA from BALB/c lymphocytes other than the subject clone.
  • the mRNA that does not hybridize will be rich for the message coding for the desired immunoglobulin chains. As necessary, this process can be repeated to further enhance the desired mRNA levels.
  • the subtracted mRNA composition may then be reverse-transcribed to provide for a cDNA mixture enriched for the desired sequences.
  • the RNA may be hydrolyzed with an appropriate RNAse and the ssDNA made double-stranded with DNA poly erase I and random primers, e.g., randomly fragmented calf thy us DNA.
  • the resulting dsDNA may then be cloned by insertion into an appropriate vector, e.g., virus vectors, such as lambda vectors or plasmid vectors (such as pBR322, pACYC184, etc.).
  • virus vectors such as lambda vectors or plasmid vectors (such as pBR322, pACYC184, etc.).
  • those cDNA clones having the gene coding for the desired light and heavy chains can be identified by hybridization.
  • the genes may be excised from the plasmids, manipulated to remove superfluous DNA upstream from the initiation codon or constant region DNA, and then introduced in an appropriate vector for transformation of a host and ultimate expression of the gene.
  • mammalian hosts e.g, mouse cells
  • process the chain e.g., join the heavy and light chains
  • secrete the immunoglobulin free of the leader sequence if desired.
  • the immunoglobulins can be prepared and processed so as to be assembled and glycosylated in cells other than mammalian cells.
  • each of the chains may be truncated so as to retain at least the variable region, which regions may then be manipulated to provide for other immunoglobulins or fragment specific for the cachectin epitopes (see, e.g., European patent application publication numbers 0239400 and 0125023, which are incorporated herein by reference) .
  • the monoclonal antibodies of the present invention are particularly useful because of their high affinity for epitopes of human cachectin. Also, some of the monoclonal antibodies are protective in vivo, permitting incorporation into pharmaceutical products, such as antibody combinations for bacterial infections.
  • Monoclonal antibodies of the present invention can also find a wide variety of utilities in vitro.
  • the monoclonal antibodies can be utilized for purifying native or recombinant human cachectin, for selectively removing human cachectin in a heterogeneous mixture of proteins, or the like.
  • the monoclonal antibodies may either be labeled or unlabeled.
  • the diagnostic assays entail detecting the formation of a complex through the binding of the monoclonal antibody to the protein.
  • the antibodies find use in agglutination assays.
  • unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the monoclonal antibody, such as antibodies specific for immunoglobulin.
  • the monoclonal antibodies can be directly labeled.
  • labels may be employed, such as radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens) , etc.
  • the monoclonal antibodies of the present invention are utilized in enzyme immunoassays, where the subject antibodies, or second antibodies from a different species, are conjugated to an enzyme.
  • an enzyme immunoassay where the subject antibodies, or second antibodies from a different species, are conjugated to an enzyme.
  • a sample containing human cachectin such as human blood or lysate thereof
  • binding occurs between the antibodies and those molecules exhibiting the desired epitope.
  • Such complexes may then be separated from the unbound reagents, and a second antibody (labeled with an enzyme) added. Thereafter, the presence of the antibody-enzyme conjugate specifically bound to the cells is determined.
  • Other conventional techniques well known to those skilled in the art may also be utilized.
  • Kits can also be supplied for use with the subject antibodies for detecting human cachectin in solutions or the presence of human cachectin epitopes in recombinant fractions.
  • the subject monoclonal antibody composition of the present invention may be provided, usually in a lyophilized form, either alone or in conjunction with antibodies specific for endotoxins, exotoxins or gram-negative bacteria.
  • the antibodies which may be conjugated to a label or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., bovine serum albumin, or the like. Generally, these material will be present in less than about 5% wt.
  • the amount of active antibody based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% wt. of the total composition.
  • a second antibody capable of binding to the monoclonal antibody this will usually be present in a separate vial.
  • the second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.
  • the monoclonal antibodies of this invention can also be incorporated as components of pharmaceutical compositions containing a therapeutic or prophylactic amount of at least one, but commonly a mixture comprising two or more, of the monoclonal antibodies of this invention with a pharmaceutically effective carrier.
  • a pharmaceutical carrier should be any compatible, non-toxic substance suitable to deliver the monoclonal antibodies to the patient. Sterile water, alcohol, fats, waxes, and . inert solids.may be used as the carrier. Pharmaceutically accepted adjuvants (buffering agents, dispersing agents) may also be incorporated into the pharmaceutical composition.
  • Such compositions can contain monoclonal antibodies specific only for human cachectin.
  • a pharmaceutical composition can contain monoclonal antibodies reactive directly with bacteria can be utilized to form a "cocktail."
  • a cocktail containing monoclonal antibodies against human cachectin epitopes and against groups of the various bacterial strains (e.g., different serotypes) causing sepsis would be a universal product with activity against the great majority of the clinical isolates responsible for the disease.
  • the mole ratio of the various monoclonal antibody components will usually not differ by more than a factor of ⁇ o, more usually by not more than a factor of 5, and will usually be in a mole ratio of about 1:1-2 to each of the other antibody components.
  • the monoclonal antibodies of the present invention will be generally used in equal molor ratios.
  • the monoclonal antibodies of the present invention may also be used in combination with existing blood plasma products, such as commercially available gamma globulin and immune globulin products used in prophylactic or therapeutic treatment of bacterial sepsis in humans.
  • the plasma will be obtained from human donors exhibiting elevated levels of immunoglobulins reactive with endotoxin bearing bacteria. (See, generally, the compendium "Intravenous Immune Globulin and the Compromised Host," Amer. J. Med. , 76(3a), March 30, 1984, pp.1-231, which is incorporated herein by reference.)
  • the monoclonal antibodies can also be used as separately administered compositions given in conjunction with antibiotics or antimicrobial agents.
  • the antimicrobial agents may include a penicillin in conjunction with an aminoglycoside (e.g., gentamicin, tobramycin, etc.), but numerous additional agents (e.g., cephalosporins) well-known to those skilled in the art may also be utilized.
  • the monoclonal antibodies and pharmaceutical compositions thereof of this invention are particularly useful for oral or parenteral administration.
  • the pharmaceutical compositions may be administered parenterally, i.e., subcutaneously, intramuscularly, intraarterially or intravenously.
  • compositions for parenteral administration which comprise a solution of the monoclonal antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier.
  • an acceptable carrier preferably an aqueous carrier.
  • aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
  • the concentration of antibody in these formulations can vary widely, i.e., from less than about 0.5%, usually at or at least bout 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc. , preferably for the particular mode of administration selected.
  • a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 500 mg of monoclonal antibody.
  • a typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of monoclonal antibody.
  • Actual methods for preparing parenterally ad inistrable compositions will be known or apparent, to those skilled in the art and are described in more detail in, for example. Remington's Pharmaceutical Science, 15 Ed., Mack Publishing Company, Easton, Pennsylvania (1980) , which is incorporated herein by reference.
  • the monoclonal antibodies of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate.
  • the compositions containing the present monoclonal antibodies or a cocktail thereof can be administered for the prophylactic and/or therapeutic treatment of any of a variety of bacterial infections.
  • compositions are administered to a patient already infected with one or more bacterial strains in an amount sufficient to cure or at least partially arrest the infection and its complications.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per kilogram of body weight with dosages of from 5 to 25 mg per kilogram being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is, life-threatening or potentially life-threatening situations, especially bacteremia and endotoxemia.
  • compositions containing the present antibody or a cocktail thereof are administered to a patient not already infected to enhance the patient's resistance to potential infections. Such an amount is defined to be a "prophylactically effective does.” In this use, the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per kilogram, especially 0.5 to 2.5 mg per kilogram. Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat or prophylax the patient.
  • Recombinant human cachectin (Pennica, et al., Nature, 312:724-729 (1984) and Shirai, et al., Nature, 313:803-806 (1985) , both of which are incorporated herein by reference) was expressed as an intracellular protein in yeast from a synthetic gene encoding an initiation methionine and the sequence of mature cachectin, with codons chosen to reflect that of highly expressed yeast genes in accordance with standard techniques.
  • the synthetic sequences were placed downstream from a hybrid alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAPDH) promoter.
  • Cachectin synthesis was induced in transformed cultures of Saccharomyces cerevisiae by glucose deprivation. About 5-10% of total yeast protein was cachectin.
  • the cachectin was purified from crude yeast extracts by (a) Ammonium sulfate fractionation, (b) Q-Sepharose Fast Flow Column Chromatography, (c) S-Sepharose Fast Flow Column Chromatography, and (d) Sepharcryl S-200 (HR) Column Chromatography. This procedure gave about 80% recovery of cachectin activity as assayed with actinomycin D-treated L929 cells (Ruff and Gifford, (1981) Tumor Necrosis Factor, Lymphokines, 2_:235-272). The specific activity of purified
  • Q cachectin was 2-4 x 10 units/mg, and the purity greater than 98% as judged by SDS polyacrylamide gel electrophoresis.
  • mice were immunized intraperitoneally with 5 to 25 ⁇ g Freund's complete adju ⁇ ant, and boosted twice with the same dose in Freund's incomplete adjuvant at 3 weekly intervals. A final intraperitoneal boost of the same dose in aqueous solution was given, and the fusion performed 3 to 4 days later.
  • mice 7 mice were fused w th about 2 x 10 myeloma cells (P3-X63-Ag8.653) (Kearney et al., J. Immunol. (1979) 123:1548-1550) using polyethylene glycol according to Kohler and Milstein (Nature 256:495 (1979)).
  • the cells were plated in microtiter plates, and the hybrids were selected by hypoxanthine aminopterin thymidine (HAT) medium.
  • HAT hypoxanthine aminopterin thymidine
  • hybrids from positive wells were cloned 3 times by limit dilutions to make certain that each was a true clone.
  • Fourteen hybridomas positive for cachectin were cloned and characterized.
  • TNF activity was measured using a cytolytic assay with actinomycin D-treated L929 cells as described by Ruff and Gifford in Lymphokines :2 5, (1981), which is incorporated herein by reference.
  • L929 cells (CCL1, American Type Culture Collection, Rockville, MD) are maintained in RPMI 1640 supplemented with lOmM Hepes and 10% fetal bovine serum (or DME + 10% FBS) .
  • Confluent cultures (3-4x10 cells/75 cm flask) are released by brief trypsin treatment (rinsing with 0.05% trypsin) in physiologic salt solution containing 5 mM EDTA and 10 mM Hepes, pH 7.4 and resuspended in fresh medium containing actimonycin D (1 g/ml) .
  • the cells are described in RPMI 1640 supplemented with lOmM Hepes and 10% fetal bovine serum (or DME + 10% FBS) .
  • Confluent cultures (3-4x10 cells/75 cm flask) are released by brief trypsin treatment (rinsing with 0.05% trypsin) in physiologic salt solution containing 5 mM EDTA and 10
  • Recombinant human cachectin (20 ng/ml in 0.02 M Tris NCI, pH 8.0, 0.15 M NaCl, 1 mg/ml BSA) is mixed with equal volumes of diluted antibody and incubated at 37*C for 60 minutes. The mixture is diluted 1:10 with fresh medium containing actinomycin D ( ⁇ g/ml) ; and 0.1 ml of serially diluted (two-fold) samples in quadruplicate is added to microtiter dish wells. The residual cytolytic activity is determined using the L929-cell cytotoxicity assay.
  • Table 1 MAb 2-2-3E3, which recognizes the same epitope as MAb 18-1-1, is required in 1/8 the amount of 18-1-1 for cell protection. Also shown in Table 1, is that most of the antibodies of the same specificity as 18-1-1 neutralized cachectin (at 100%) in the L929 cell killing
  • Hybridoma MAb, type Competition assay Neutralization Ass with 18-l-l b Medium Purified 59
  • Intestines Normal in appearance but intussusceptions in small intestine were observed in animals #1,2.
  • the cell lines of the present invention provide means for producing monoclonal antibodies and fragments thereof reactive with human cachectin at low neutralizing amounts. This allows prophylactic and therapeutic compositions to be more economically developed and safely administered to be effective against infections due to most endotoxin bearing bacterial strains.
  • the antibodies will find uses in various diagnostic and other therapeutic procedures.

Abstract

Cell lines are provided that produce improved neutralizing monoclonal antibodies reactive with human cachectin. The antibodies have various therapeutic and diagnostic uses.

Description

MONOCLONAL ANTIBODIES REACTIVE WITH CACHECTIN
FIELD OF THE INVENTION
The present invention relates to the application of immunological techniques to provide novel materials useful in diagnosing and treating, inter alia, bacterial infection, and, more particularly, to the production and application of improved monoclonal antibodies that are capable of specifically reacting with human cachectin.
BACKGROUND OF THE INVENTION
The introduction of invasive stimuli, such as parasitic, bacterial or viral infections, or neoplastic cells, induce significant metabolic changes in the susceptible host. If serious, the changes may eventually disrupt normal homeostatic mechanisms, both locally and systemically, leading to the depletion of host energy stores advancing to wasting (Cachexia) , tissue damage, multiple organ system failure, shock and death. Until recently, clinicians believe that the systematic patterns were primarily due to actions of the invasive agents themselves. However, it is now known that the invasive stimuli caused the host to generate various cytokines, the combined actions of which cause most of the undesirable biological responses. These host-derived inflammatory mediators present new opportunities for developing treatment regimens against a wide variety of inflammatory disease states.
One of the most potent cytokines is cachectin, which is primarily released by macrophages after appropriate stimulation. Cachectin, also known as Tumor Necrosis Factor, is a protein having 157 amino acids normally found in vivo as a dimer or other multimer. The calculated molecular weight of human TNF monomer is about 17,000 daltons.
Cachectin acts to suppress biosynthesis of several adipocyte-specific proteins, such as lipoprotein lipase. It also acts to induce the biosynthesis or release of numerous other proteins, including Class I major histocompatibility antigen, granulocyte- acrophage-colony stimulating factor, and interleukin 1. (See, generally, Beutler and Cerami, New Eng. J. of Med., 3l6;379-385 (1987), which is incorporated herein by reference.)
The recognition of cachectin's broad influence on various disease states has led to attempts in controlling its actions. For example, experiments have shown that antibodies specifically reactive with cachectin may be therapeutically useful in controlling the immunomodulatory responses now known to be associated with cachectin (see, U. S. Patent Nos. 4,603,106 and 4,684,623, both of which are incorporated herein by reference) . In particular, neutralizing antibodies capable of binding various epitopes on human cachectin at high affinity have significant potential for mediating the toxic effects of excess cachectin levels.
Thus, there exists a need for improved antibodies capable of neutralizing the toxic effects of cachectin in vivo. The present invention fulfills these needs.
SUMMARY OF THE INVENTION
Novel cell lines are provided which produce monoclonal antibodies capable of binding to human cachectin epitopes with enhanced neutralization capability in vivo. Additionally, methods are provided for treating a human susceptible to bactere ia or sepsis or already infected with an endotoxin-bearing bacteria by administering a prophylactic or therapeutic amount of a composition comprising at least .one monoclonal antibody or binding fragment thereof capable of reacting with human cachectin and exhibiting neutralizing activity in an L929 cell cytolytic assay at less than about 400ng, typically between about 50 to 200 ng or more, the composition preferably further including a physiologically acceptable carrier. The composition may also contain any one or more of the following: additional monoclonal antibodies capable of reacting with bacterial endotoxins or exotoxins; monoclonal antibodies capable of reacting with serotype determinants on particular bacterial strains bearing endotoxins; a gamma globulin fraction from human blood plasma; a gamma globulin fraction from human blood plasma, where the plasma may be obtained from a human exhibiting elevated levels of immunoglobulins reactive with bacterial endotoxins; and one or more antimicrobial agents. Further, clinical uses of the monoclonal antibodies are provided, including the production of diagnostic kits.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
In accordance with the present invention, novel cells capable of producing neutralizing monoclonal antibodies of desired affinities and compositions comprising such antibodies are provided, such compositions being capable of selectively recognizing epitopes present on human cachectin. The subject cells have identifiable chromosomes in which the germ-line DNA from them or a precursor cell has rearranged to encode an antibody having a binding site for a desired epitope on human cachectin. These monoclonal antibodies can be used in a wide variety of ways, including diagnosis and therapy.
The monoclonal antibodies so provided are particularly useful, when compared to prior art antibodies, in the treatment or prophylaxis of serious diseases, such as bacteremia, sepsis, cachexia, or other disease states associated with elevated levels of cachectin. Thus, the antibodies will typically have neutralizing activity at less than 400 ng, perferably less than about 300 ng, most preferably about 50 to 200 ng, in the L929 cell cytolytic assay. This higher level of activity permits utilizing significantly lower dosage levels for treatments. The preparation of monoclonal antibodies can be accomplished by immortalizing a cell line capable of expressing nucleic acid sequences that code for antibodies specific for an appropriate epitope on human cachectin. The immortalized cell line may be a mammalian cell line that has been transformed through oncogenesis, by transfection, mutation, or the like. Such cells include myeloma lines, lymphoma lines, or other cell line capable of supporting the expression and secretion of the immunoglobulin, or binding fragment thereof, in vitro. The immunoglobulin or fragment may be a naturally-occurring immunoglobulin of a mammal other than the preferred mouse or human sources, produced by transformation of a lymphocyte, particularly a splenocyte, by means of a virus or by fusion of the lymphocyte with a neoplastic cell, e.g., a myeloma, to produce a hybrid cell line. Typically, the splenocyte will be obtained from an animal immunized against cachectin-related antigens or fragments thereof containing an epitopic site. Immunization protocols are well known and can vary considerably yet remain effective. (See, Goding, Monoclonal Antibodies: Principles and
Practice, 2d Ed., Academic Press, N.Y. [1986], which is incorporated herein by reference.)
The hybrid cell lines may be cloned and screened in accordance with conventional techniques, and antibodies in the cell supernatants detected that are capable of binding to the desired human cachectin determinants with appropriate affinities. The appropriate hybrid cell lines may then be grown in large-scale culture or injected into the peritoneal cavity of an appropriate host for production of antibodies ascites fluid.
By virtue of having the antibodies of the present invention, which are known to be specific for the human cachectin protein, in some cases the supernatants of subsequent experiments may be screened in a competition assay with the subject monoclonal antibodies as a means to identify additional examples of the desired anti-human cachectin monoclonal antibodies (so-called "blocking antibodies") . Thus, hybrid cell lines can be readily produced from a variety of sources based on the availability of present antibodies specific for the particular cachectic determinants at the appropriate affinity levels.
Alternatively, where hybrid cell lines are available that produce antibodies specific for the subject epitopic sites, these hybrid cell lines may be fused with other neoplastic B-cells, where such other B-cells may serve as recipients for genomic DNA coding for the antibodies. These antibodies may be functional at the cell surface and not, for example, as receptors. While rodent, particularly murine, neoplastic B-cells are most commonly utilized, other mammalian species may be employed, such as lagomorpha, bovine, ovine, equine, porcine, avian or the like.
The monoclonal antibodies may be of any of the classes or subclasses of immunoglobulins, such as IgM, IgD, IgA, IgE, or subclasses of IgG known for each species of animal. Generally, the monoclonal antibodies may be used intact, or as binding fragments, such as Fv, Fab, F(ab')2, but usually intact.
The cell lines of the present invention may find use other than for the direct production of the monoclonal antibodies. The cell lines may be fused with other cells
(such as suitably drug-marked human myeloma, mouse myelomas or human lymphoblastoid cells) to produce hybridomas or triomas, and thus provide for the transfer of the genes encoding the monoclonal antibodies. Alternatively, the cell lines may be used as a source of the chromosomes encoding the immunoglobulins, which may be isolated and transferred to cells by techniques other than fusion. In addition, the genes encoding the monoclonal antibodies may be isolated and used in accordance with recombinant DNA techniques for the production of the specific immunoglobulin in a variety of hosts. Particularly, by preparing cDNA libraries from messenger RNA, a single cDNA clone, coding for the immunoglobulin and free of introns, may be isolated and placed into suitable prokaryotic or eukaryotic expression vectors and subsequently transformed into a host for ultimate bulk production. (See, generally, U. S. Nos. 4,172,124; 4,350,683; 4,363,799; 4,381,292; and 4,423,147. See also, Kennett, et al., Monoclonal Antibodies, Plenum, New York [1980], and references cited therein, al of which are incorporated herein by reference.) More specifically, in accordance with hybrid DNA technology, the immunoglobulins or fragments of the present invention may be produced in bacteria or yeast. (See, Boss, et al., Nucl. Acid. Res., 12:3791 and Wood, et al., Nature 314:446, both of which are incorporated herein by reference.) For example, the messenger RNA transcribed from the genes coding for the light and heavy chains of the monoclonal antibodies produced by a cell line of the present invention may be isolated by differential cDNA hybridization employing cDNA from BALB/c lymphocytes other than the subject clone. The mRNA that does not hybridize will be rich for the message coding for the desired immunoglobulin chains. As necessary, this process can be repeated to further enhance the desired mRNA levels. The subtracted mRNA composition may then be reverse-transcribed to provide for a cDNA mixture enriched for the desired sequences. The RNA may be hydrolyzed with an appropriate RNAse and the ssDNA made double-stranded with DNA poly erase I and random primers, e.g., randomly fragmented calf thy us DNA. The resulting dsDNA may then be cloned by insertion into an appropriate vector, e.g., virus vectors, such as lambda vectors or plasmid vectors (such as pBR322, pACYC184, etc.). By developing probes based on known sequences for the constant regions of the light and heavy chains, those cDNA clones having the gene coding for the desired light and heavy chains can be identified by hybridization. Thereafter, the genes may be excised from the plasmids, manipulated to remove superfluous DNA upstream from the initiation codon or constant region DNA, and then introduced in an appropriate vector for transformation of a host and ultimate expression of the gene.
Conveniently, mammalian hosts (e.g, mouse cells) may be employed to process the chain (e.g., join the heavy and light chains)" to produce an intact immunoglobulin, and furthermore, secrete the immunoglobulin free of the leader sequence, if desired. Alternatively, one may use unicellular microorganisms for producing the two chains, where further manipulation may be required to remove the DNA sequences coding for the secretory leader and processing signals, while providing for an initiation codon at the 5' terminus of the sequence coding for the heavy chain. In this manner, the immunoglobulins can be prepared and processed so as to be assembled and glycosylated in cells other than mammalian cells. If desired, each of the chains may be truncated so as to retain at least the variable region, which regions may then be manipulated to provide for other immunoglobulins or fragment specific for the cachectin epitopes (see, e.g., European patent application publication numbers 0239400 and 0125023, which are incorporated herein by reference) .
The monoclonal antibodies of the present invention are particularly useful because of their high affinity for epitopes of human cachectin. Also, some of the monoclonal antibodies are protective in vivo, permitting incorporation into pharmaceutical products, such as antibody combinations for bacterial infections.
Monoclonal antibodies of the present invention can also find a wide variety of utilities in vitro. By way of example, the monoclonal antibodies can be utilized for purifying native or recombinant human cachectin, for selectively removing human cachectin in a heterogeneous mixture of proteins, or the like.
For diagnostic purposes, the monoclonal antibodies may either be labeled or unlabeled. Typically, the diagnostic assays entail detecting the formation of a complex through the binding of the monoclonal antibody to the protein. When unlabeled, the antibodies find use in agglutination assays. In addition, unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the monoclonal antibody, such as antibodies specific for immunoglobulin. Alternatively, the monoclonal antibodies can be directly labeled. A wide variety of labels may be employed, such as radionuclides, fluorescers, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (particularly haptens) , etc. Numerous types of immunoassays are available, and by way of example, some include those described in U. S. Patent Nos. 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876, all of which are incorporated herein by reference.
Commonly, the monoclonal antibodies of the present invention are utilized in enzyme immunoassays, where the subject antibodies, or second antibodies from a different species, are conjugated to an enzyme. When a sample containing human cachectin, such as human blood or lysate thereof, is combined with the subject antibodies, binding occurs between the antibodies and those molecules exhibiting the desired epitope. Such complexes may then be separated from the unbound reagents, and a second antibody (labeled with an enzyme) added. Thereafter, the presence of the antibody-enzyme conjugate specifically bound to the cells is determined. Other conventional techniques well known to those skilled in the art may also be utilized. Kits can also be supplied for use with the subject antibodies for detecting human cachectin in solutions or the presence of human cachectin epitopes in recombinant fractions. Thus, the subject monoclonal antibody composition of the present invention may be provided, usually in a lyophilized form, either alone or in conjunction with antibodies specific for endotoxins, exotoxins or gram-negative bacteria. The antibodies, which may be conjugated to a label or unconjugated, are included in the kits with buffers, such as Tris, phosphate, carbonate, etc., stabilizers, biocides, inert proteins, e.g., bovine serum albumin, or the like. Generally, these material will be present in less than about 5% wt. based on the amount of active antibody, and usually present in total amount of at least about 0.001% wt. based again on the antibody concentration. Frequently, it will be desirable to include an inert extender or excipient to dilute the active ingredients, where the excipient may be present in from about 1 to 99% wt. of the total composition. Where a second antibody capable of binding to the monoclonal antibody is employed, this will usually be present in a separate vial. The second antibody is typically conjugated to a label and formulated in an analogous manner with the antibody formulations described above.
The monoclonal antibodies of this invention can also be incorporated as components of pharmaceutical compositions containing a therapeutic or prophylactic amount of at least one, but commonly a mixture comprising two or more, of the monoclonal antibodies of this invention with a pharmaceutically effective carrier. A pharmaceutical carrier should be any compatible, non-toxic substance suitable to deliver the monoclonal antibodies to the patient. Sterile water, alcohol, fats, waxes, and . inert solids.may be used as the carrier. Pharmaceutically accepted adjuvants (buffering agents, dispersing agents) may also be incorporated into the pharmaceutical composition. Such compositions can contain monoclonal antibodies specific only for human cachectin.
Alternatively, a pharmaceutical composition can contain monoclonal antibodies reactive directly with bacteria can be utilized to form a "cocktail." For example, a cocktail containing monoclonal antibodies against human cachectin epitopes and against groups of the various bacterial strains (e.g., different serotypes) causing sepsis would be a universal product with activity against the great majority of the clinical isolates responsible for the disease.
The mole ratio of the various monoclonal antibody components will usually not differ by more than a factor of ιo, more usually by not more than a factor of 5, and will usually be in a mole ratio of about 1:1-2 to each of the other antibody components. When used in combination, the monoclonal antibodies of the present invention will be generally used in equal molor ratios. The monoclonal antibodies of the present invention may also be used in combination with existing blood plasma products, such as commercially available gamma globulin and immune globulin products used in prophylactic or therapeutic treatment of bacterial sepsis in humans. Preferably, for immune globulins the plasma will be obtained from human donors exhibiting elevated levels of immunoglobulins reactive with endotoxin bearing bacteria. (See, generally, the compendium "Intravenous Immune Globulin and the Compromised Host," Amer. J. Med. , 76(3a), March 30, 1984, pp.1-231, which is incorporated herein by reference.)
The monoclonal antibodies can also be used as separately administered compositions given in conjunction with antibiotics or antimicrobial agents. Typically, the antimicrobial agents may include a penicillin in conjunction with an aminoglycoside (e.g., gentamicin, tobramycin, etc.), but numerous additional agents (e.g., cephalosporins) well-known to those skilled in the art may also be utilized. The monoclonal antibodies and pharmaceutical compositions thereof of this invention are particularly useful for oral or parenteral administration. Preferably, the pharmaceutical compositions may be administered parenterally, i.e., subcutaneously, intramuscularly, intraarterially or intravenously. Thus, this invention provides compositions for parenteral administration which comprise a solution of the monoclonal antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. The concentration of antibody in these formulations can vary widely, i.e., from less than about 0.5%, usually at or at least bout 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc. , preferably for the particular mode of administration selected.
Thus, a typical pharmaceutical composition for intramuscular injection could be made up to contain 1 ml sterile buffered water, and 500 mg of monoclonal antibody. A typical composition for intravenous infusion could be made up to contain 250 ml of sterile Ringer's solution, and 150 mg of monoclonal antibody. Actual methods for preparing parenterally ad inistrable compositions will be known or apparent, to those skilled in the art and are described in more detail in, for example. Remington's Pharmaceutical Science, 15 Ed., Mack Publishing Company, Easton, Pennsylvania (1980) , which is incorporated herein by reference.
The monoclonal antibodies of this invention can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with conventional immune globulins and art-known lyophilization and reconstitution techniques can be employed. It will be appreciated by those skilled in the art that lyophilization and reconstitution can lead to varying degrees of antibody activity loss (e.g., with conventional immune globulins, IgM antibodies tend to have greater activity loss than IgG antibodies) and that use levels may have to be adjusted to compensate. The compositions containing the present monoclonal antibodies or a cocktail thereof can be administered for the prophylactic and/or therapeutic treatment of any of a variety of bacterial infections. In therapeutic application, compositions are administered to a patient already infected with one or more bacterial strains in an amount sufficient to cure or at least partially arrest the infection and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this will depend upon the severity of the infection and the general state of the patient's own immune system, but generally range from about 1 to about 200 mg of antibody per kilogram of body weight with dosages of from 5 to 25 mg per kilogram being more commonly used. It must be kept in mind that the materials of this invention may generally be employed in serious disease states, that is, life-threatening or potentially life-threatening situations, especially bacteremia and endotoxemia.
In prophylactic applications, compositions containing the present antibody or a cocktail thereof are administered to a patient not already infected to enhance the patient's resistance to potential infections. Such an amount is defined to be a "prophylactically effective does." In this use, the precise amounts again depend upon the patient's state of health and general level of immunity, but generally range from 0.1 to 25 mg per kilogram, especially 0.5 to 2.5 mg per kilogram. Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician. In any event, the pharmaceutical formulations should provide a quantity of the antibody(ies) of this invention sufficient to effectively treat or prophylax the patient.
EXPERIMENTAL
Production and Purification of Cachectin
Recombinant human cachectin (Pennica, et al., Nature, 312:724-729 (1984) and Shirai, et al., Nature, 313:803-806 (1985) , both of which are incorporated herein by reference) was expressed as an intracellular protein in yeast from a synthetic gene encoding an initiation methionine and the sequence of mature cachectin, with codons chosen to reflect that of highly expressed yeast genes in accordance with standard techniques. The synthetic sequences were placed downstream from a hybrid alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAPDH) promoter. Cachectin synthesis was induced in transformed cultures of Saccharomyces cerevisiae by glucose deprivation. About 5-10% of total yeast protein was cachectin. The cachectin was purified from crude yeast extracts by (a) Ammonium sulfate fractionation, (b) Q-Sepharose Fast Flow Column Chromatography, (c) S-Sepharose Fast Flow Column Chromatography, and (d) Sepharcryl S-200 (HR) Column Chromatography. This procedure gave about 80% recovery of cachectin activity as assayed with actinomycin D-treated L929 cells (Ruff and Gifford, (1981) Tumor Necrosis Factor, Lymphokines, 2_:235-272). The specific activity of purified
Q cachectin was 2-4 x 10 units/mg, and the purity greater than 98% as judged by SDS polyacrylamide gel electrophoresis. Production of Monoclonal Antibodies to Cachectin
BALB/c mice were immunized intraperitoneally with 5 to 25 μg Freund's complete adjuσant, and boosted twice with the same dose in Freund's incomplete adjuvant at 3 weekly intervals. A final intraperitoneal boost of the same dose in aqueous solution was given, and the fusion performed 3 to 4 days later.
8
Spleen cells (about 10 cells) from immunized
7 mice were fused w th about 2 x 10 myeloma cells (P3-X63-Ag8.653) (Kearney et al., J. Immunol. (1979) 123:1548-1550) using polyethylene glycol according to Kohler and Milstein (Nature 256:495 (1979)). The cells were plated in microtiter plates, and the hybrids were selected by hypoxanthine aminopterin thymidine (HAT) medium.
Five fusions were performed with spleen cells from five mice immunized with cachectin. By using the solid phase enzyme-linked immunosorbent assays, 60 positive clones were obtained producing monoclonal antibodies to cachectin.
The hybrids from positive wells were cloned 3 times by limit dilutions to make certain that each was a true clone. Fourteen hybridomas positive for cachectin were cloned and characterized.
Cachectin/TNF Bioassay: L-929 Cell Cytotoxicity
TNF activity was measured using a cytolytic assay with actinomycin D-treated L929 cells as described by Ruff and Gifford in Lymphokines :2 5, (1981), which is incorporated herein by reference.
L929 cells (CCL1, American Type Culture Collection, Rockville, MD) are maintained in RPMI 1640 supplemented with lOmM Hepes and 10% fetal bovine serum (or DME + 10% FBS) . Confluent cultures (3-4x10 cells/75 cm flask) are released by brief trypsin treatment (rinsing with 0.05% trypsin) in physiologic salt solution containing 5 mM EDTA and 10 mM Hepes, pH 7.4 and resuspended in fresh medium containing actimonycin D (1 g/ml) . The cells are
4 then plated in 96 well microtiter dishes (5-7x10 cells/well) .
After 2 hours in culture, serially diluted samples are added to wells, (less than 10-20% serum), and plates incubated overnight (5% C02, 37"C). Samples are assayed in quadruplicate. The next day, following microscopic evaluation, the medium is decanted, and the wells filled with a solution of 0.2% crystal violet, 10% formalin and 0.01 phosphate pH 7-7.5 for 5 min., washed thoroughly with water and dried. The degree of lysis is quantitated spectrophotometrically (550-570 nM) on a microtiter plate reader. Assay results are expressed as U/ml, with one unit (U) defined as the amount of cachectin resulting in lysis of 50% of the cells.
In Vitro Neutralization Assay
Recombinant human cachectin (20 ng/ml in 0.02 M Tris NCI, pH 8.0, 0.15 M NaCl, 1 mg/ml BSA) is mixed with equal volumes of diluted antibody and incubated at 37*C for 60 minutes. The mixture is diluted 1:10 with fresh medium containing actinomycin D (μg/ml) ; and 0.1 ml of serially diluted (two-fold) samples in quadruplicate is added to microtiter dish wells. The residual cytolytic activity is determined using the L929-cell cytotoxicity assay.
Characterization of Monoclonal Antibodies
Fourteen hybridomas positive for cachectin were identified and subcloned. The antibodies produced by these hybridomas were characterized for their ability to compete with monoclonal antibody 18-1-1. (Tracey, et al., Nature 330:662-664 (1987), which is incorporated herein by reference) for cachectin binding in an ELISA. As shown in Table 1, the monoclonal antibodies fall into three classes; those that do not compete with 18-1-1, those that do, and those that show intermediate competition. To verify that those monoclonal antibodies which did not compete with 18-1-1 were specific for cachectin, a cachectin capture assay was performed. On a solid phase were bound the monoclonal antibodies to capture cachectin, and monoclonal antibody 18-1-1 was used as the labeled antibody. All the 5 monoclonal antibodies were specific for cachectin by this assay.
Experiments with conditioned media from hybridoma cells were also performed to determine the extent the Mabs neutralized the cell killing activity of cachectin. All of
10 the 14 monoclonal antibodies were produced in mouse ascites fluid for further characterization. The efficacy of the purified monoclonal antibodies in protecting L929 cells against killing by cachectin was determined. The neutralizing activity of MAb 1-2-4B1 had been confirmed
15 with the purified material. Incubation of MAb 2-2-3E3 (50 ng/ml) with an equal volume of human recombinant cachectin (20 ng/ml) at 37* for 60 min., showed that 50% of the cytolytic activity of cachectin was neutralized as determined by the L929 cell killing assay. As shown in
20 Table 1, MAb 2-2-3E3, which recognizes the same epitope as MAb 18-1-1, is required in 1/8 the amount of 18-1-1 for cell protection. Also shown in Table 1, is that most of the antibodies of the same specificity as 18-1-1 neutralized cachectin (at 100%) in the L929 cell killing
25 assay. Other antibodies, such as 1-2-4B1, which have different epitope specificities from that of 18-1-1, also possessed significant neutralizing activity.
'30
35 Table 1
Profile of Monoclonal Antibodies Reactive with Human Cachectin
Hybridoma MAb, type= Competition assay Neutralization Ass with 18-l-lb Medium Purified 59
+ + 400
+ +
+ 400
+ + + >800
+ + + 50
+ +
+ + 200
+ +
± ' +
Figure imgf000019_0001
•f
a) Determined by SDS-PAGE of MAb partially purified from ascites fluid by precipitation with ammonium sulfate.
b) Determined in a Solid Phase Competition ELISA as follows. Conditioned medium from 24 hr hybridoma cultures (50 l) and HRP-labelled 18-1-1 (25/zl, 0.2 μg/ml in PBS + 10% goat serum) were added to each well. c) The cell lines 1-2-4B1 and 2-2-3E3 were deposited with the A.T.C.C. and designated Accession Numbers HB9737 and HB9736, respectively.
Efficacy of post-treatment with anti-TNF monoclonal antibody fragment in preventing the deleterious effects of sepsis in the baboon.
Baboons were intravenously administered a two hour LD100 infusion of Escherichia coli (E. coli) . Animals were monitored for 10 hours and observed until death, or for a maximum of 7 days. The aminoglycoside antibiotic, gentamicin, was administered at designated times following a two hour infusion of E^_ coli. A bolus injection of anti-TNF monoclonal antibody 2-2-3E3 F(ab')2 fragment (10 mg/kg) was administered to four baboons at T+30 minutes (one-quarter of the way through the bacterial infusion, i.e., "post-treatment"). One additional baboon was given the same dose of E coli lus entamicin and treated with
Figure imgf000020_0001
Summary of post-mortem examinations conducted on baboons #1,2,5, (post-mortems not included on surviving baboons #3,4 because prior work with surviving animals showed no adverse histological effects) . The gross post mortem findings on animals #1,2,5 were very similar to each other and are as follows: ++ Lungs: Hemorrhagic (3 )
+++ Kidneys: Congested, necrotic (3 )
Adrenals: Hemorrhagic, necrotic (4 )
Liver: Congested (2 ) Spleen: Engorged and congested
Intestines: Normal in appearance but intussusceptions in small intestine were observed in animals #1,2.
Heart, pancreas, stomach, colon: Normal in appearance.
(3) Physiological and other parameters monitored for ten hours
(a) Parameters associated with survival benefits in baboons #3,4 and different from nonsurviving baboons (#1,2,5) were: TMean systemic arterial pressure (MSAP) , TpH, -ilactate, iBUN, -icreatinine, iSGPT, icortisol, Tglucose, 4-FDP and Tfibrinogen.
(b) Parameters no different between surviving (#3,4) and nonsurviving (#1,2,5) baboons were: Heart and respiration rates, WBS, platelets, pC02, p02, CPK, he atocrit, colony (E^ coli) blood concentrations, body temperature.
When the studies were repeated with whole antibody, no significant differences were noted. Thus, both binding fragments and intact antibodies may be utilized in accordance with the present invention.
From the foregoing, it will be appreciated that the cell lines of the present invention provide means for producing monoclonal antibodies and fragments thereof reactive with human cachectin at low neutralizing amounts. This allows prophylactic and therapeutic compositions to be more economically developed and safely administered to be effective against infections due to most endotoxin bearing bacterial strains. In addition, the antibodies will find uses in various diagnostic and other therapeutic procedures.
Although the present invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

Claims

1. A composition comprising a monoclonal antibody or binding fragment thereof specifically reactive with human cachectin, wherein said antibody exhibits neutralizing activity less than 400 ng in an L929 cell cytolytic assay.
2. A composition according to Claim 1, wherein the monoclonal antibody or binding fragment is capable of blocking the cachectin binding of monoclonal antibody 18-1-1.
3. A composition according to Claim 1 wherein the monoclonal antibody or binding fragment thereof is protective against endotoxemia in vivo.
4. A composition according to Claim 1, wherein the monoclonal antibody is capable of blocking the binding of monoclonal antibodies produced by a cell line designated A.T.C.C. Accession Number HB9736 or HB9737.
5. A composition comprising two or more monoclonal antibodies of binding fragments thereof, wherein said monoclonal antibodies are capable of reacting with different epitopes of human cachectin.
6. A composition according to Claim 5 wherein at least one of said monoclonal antibodies is protective in vivo.
7. A composition according to any of Claims 1 or 5, further comprising an antibiotic agent or a gamma globulin fraction from human blood plasma.
8. A composition according to Claim 5, wherein one of said monoclonal antibodies is produced by a cell line designated A.T.C.C. Accession Number HB9736 or HB9737.
5 9. A pharmaceutical composition comprising a composition according to Claims 1 or 5, and a physiologically acceptable carrier.
10. A pharmaceutical composition useful for 10 treating or preventing an infection, said composition comprising a monoclonal antibody reactive with an epitope of human cachectin and protective i vivo, an antimicrobial agent, a gamma globulin fraction from human blood plasma and a physiologically acceptable carrier. 15
11. A pharmaceutical composition according to Claim 10, wherein the gamma globulin fraction from human blood plasma is obtained from humans exhibiting elevated levels of immunoglobulins reactive with endotoxin-bearing
20 bacteria.
12. A method for treating a human susceptible to bacteremia and/or septicemia, which comprises: administering to said human a prophylactic 25 or therapeutic amount of a composition according to any of Claims 1, 5, or 10.
13. A cell line which produces a monoclonal antibody capable of specifically reacting with human
'30 cachectin, said antibody exhibiting neutralizing activity between about 50 to 400 ng in an L929 cell cytolytic assay.
14. A cell line according to Claim 13, wherein the monoclonal antibody is protective in vivo against
35 endotoxin-bearing bacteria.
15. A cell line according to Claim 13, which is designated A.T.C.C. Accession Number HB9736 or HB9737.
16. A cell line designated A.T.C.C. Accession Number HB9737.
17. A method of producing monoclonal antibodies specific for and capable pf treating or preventing endotoxin-bearing bacteria infections, said method comprising: cultivating at least one of the cell lines of Claims 15 or 16 and recovering said antibodies.
18. A method for treating a human susceptible to bacteremia and/or septicemia which comprises: administering to said human prophylactic or therapeutic amount of monoclonal antibodies produced according to Claims 15 or 16.
19. A monoclonal antibody or fragment thereof reactive with an epitope which is capable of binding to a monoclonal antibody produced according to Claim 17.
20. A monoclonal antibody composition having substantially the same binding affinity and specificity as any one of the monoclonal antibodies designated 1-2-4B1 or 2-2-3E3.
21. A monoclonal antibody according to Claim 20, conjugated to a label capable of providing a detectable signal.
22. A monoclonal antibody according to Claim 21, wherein the label is a fluorescer or an enzyme.
23. A kit for use in detecting the presence of endotoxin-bearing bacteria infection in a host, said kit comprising a monoclonal antibody composition containing monoclonal antibodies produced by the cell lines designated A.T.C.C. Accession Numbers HB9736 or HB9737 and labels providing for a detectable signal covalently bonded to said antibody or bonded to second antibodies reactive with each said monoclonal antibody.
PCT/US1989/003025 1988-07-18 1989-07-12 Monoclonal antibodies reactive with cachectin WO1990000902A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI901344A FI101937B (en) 1988-07-18 1990-03-16 Method for producing monoclonal antibody reactive with human n cachectin
NO901247A NO179615C (en) 1988-07-18 1990-03-16 Monoclonal antibodies or fragments thereof that react with cachectin, cell lines that produce them, assays comprising them, and their use in vitro
DK069890A DK69890A (en) 1988-07-18 1990-03-16 MONOCLONAL ANTIBODIES REACTIVE WITH CACHETIN
NO952509A NO180637C (en) 1988-07-18 1995-06-22 Process for producing monoclonal antibodies or fragments thereof
FI954230A FI102115B (en) 1988-07-18 1995-09-08 Monoclonal antibody composition to be used as diagnostic reagent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US220,206 1980-12-24
US22020688A 1988-07-18 1988-07-18

Publications (1)

Publication Number Publication Date
WO1990000902A1 true WO1990000902A1 (en) 1990-02-08

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003025 WO1990000902A1 (en) 1988-07-18 1989-07-12 Monoclonal antibodies reactive with cachectin

Country Status (16)

Country Link
US (1) US5658803A (en)
EP (1) EP0351789B1 (en)
JP (1) JP2638652B2 (en)
AT (1) ATE173766T1 (en)
AU (1) AU626572B2 (en)
CA (1) CA1340018C (en)
DE (1) DE68928857T2 (en)
DK (1) DK69890A (en)
ES (1) ES2124209T3 (en)
FI (1) FI101937B (en)
IL (1) IL90990A (en)
NO (1) NO179615C (en)
NZ (1) NZ229922A (en)
PT (1) PT91201B (en)
WO (1) WO1990000902A1 (en)
ZA (1) ZA895372B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001755A1 (en) * 1989-08-10 1991-02-21 Celltech Limited Pharmaceutical product for the treatment of sepsis
EP0585705A1 (en) * 1992-08-28 1994-03-09 Bayer Corporation Use of anti-TNF to treat bacterial meningitis
EP0610201A1 (en) * 1991-03-18 1994-08-17 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7101674B2 (en) 1991-03-18 2006-09-05 New York University Anti-idiotypic anti-TNF antibodies and related immunoassay methods
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7250165B2 (en) 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (en) 1989-08-07 2003-09-02 ペプテック リミテッド Tumor necrosis factor binding ligand
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
AU641178B2 (en) * 1989-08-16 1993-09-16 Cetus Oncology Corp Prohormone cleavage site blocking antibody
DE4037604A1 (en) * 1990-04-25 1991-10-31 Bayer Ag Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants
ATE197646T1 (en) * 1990-08-06 2000-12-15 Chiron Corp METHOD FOR DETECTING CYTOKINE CONVERTASE INHIBITORS
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
CA2100084A1 (en) * 1991-01-11 1992-07-12 James R. Rusche Method of preventing inflammatory damage
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
AU678483B2 (en) * 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE122004000003I2 (en) 1996-02-09 2007-03-29 Abbott Biotech Ltd Human antibodies which bind to human TNFalpha
DE19746868A1 (en) * 1997-10-23 1999-04-29 Knoll Ag Use of tumour necrosis factor antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP1578799B8 (en) 2002-12-02 2011-03-23 Amgen Fremont Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TWI439284B (en) 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd Multiple-variable dose regimen for treating tnfα-related disorders
TWI399383B (en) 2005-05-16 2013-06-21 Abbott Biotech Ltd Use of tnfα inhibitor for treatment of erosive polyarthritis
AU2006329963B2 (en) * 2005-12-06 2011-06-09 Amgen Inc. Polishing steps used in multi-step protein purification processes
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
EP2948178A4 (en) 2013-01-25 2016-07-20 Thymon Llc Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0249618A1 (en) * 1985-12-05 1987-12-23 Biogen N.V. Combinations of tumor necrosis factors and antibiotics and methods for treating tumors
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (en) * 1986-09-13 1988-03-24 Basf Ag MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 137, No. 2, issued 13 June 1986, (USA), LIANG et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin", pages 847-854. *
NATURE, Vol. 330, No. 6149, issued 17 December 1987 (London, UK), TRACEY et al., "Anti-Cachectin/TNF Monoclonal Antibodies Prevent Septic Shock During Lethal Bacteraemia", pages 662-664. *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001755A1 (en) * 1989-08-10 1991-02-21 Celltech Limited Pharmaceutical product for the treatment of sepsis
GB2251187A (en) * 1989-08-10 1992-07-01 Celltech Ltd Pharmaceutical product for the treatment of sepsis
GB2251187B (en) * 1989-08-10 1993-06-23 Celltech Ltd Antibody composition for the treatment of sepsis
US7204985B2 (en) 1991-03-18 2007-04-17 Centocor, Inc. Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
EP1097945A3 (en) * 1991-03-18 2001-10-10 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7223396B2 (en) 1991-03-18 2007-05-29 Centocor, Inc. Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
US6790444B2 (en) 1991-03-18 2004-09-14 New York University Medical Center Anti-TNF antibodies and peptides of human necrosis factor
US6835823B2 (en) 1991-03-18 2004-12-28 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6991791B2 (en) 1991-03-18 2006-01-31 New York University School Of Medicine Anti-TNF antibodies and peptides of human tumor necrosis factor
US7070775B2 (en) 1991-03-18 2006-07-04 New York University Recombinant A2-specific TNFα specific antibodies
EP1681305A2 (en) * 1991-03-18 2006-07-19 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US7101674B2 (en) 1991-03-18 2006-09-05 New York University Anti-idiotypic anti-TNF antibodies and related immunoassay methods
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7128907B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods of treating crohn's disease with anti-TNF antibodies
US7135179B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof
US7135178B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods of treating disseminated intravascular coagulation using anti-TNF antibodies
US7138118B2 (en) 1991-03-18 2006-11-21 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
US7160542B2 (en) 1991-03-18 2007-01-09 New York University Method of treating psoriasis using human anti-TNF antibodies and fragments
US7226593B2 (en) 1991-03-18 2007-06-05 Centocor, Inc. Methods of treating cachexia with chimeric anti-TNF antibodies
US7160543B2 (en) 1991-03-18 2007-01-09 New York University Methods of inhibiting TNF-α in patients with Crohn's disease
US7166284B2 (en) 1991-03-18 2007-01-23 New York University Methods of treating joint inflammation with anti-TNF antibodies
US7169388B2 (en) 1991-03-18 2007-01-30 New York University Methods of inhibiting TNFα in patients with cancer
US7169386B1 (en) 1991-03-18 2007-01-30 New York University Methods of treating inflammation associated with viral infection with anti-TNF antibodies
US7179893B2 (en) 1991-03-18 2007-02-20 New York University Recombinant anti-TNF-α antibodies
US7179466B2 (en) 1991-03-18 2007-02-20 New York University Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP0610201A1 (en) * 1991-03-18 1994-08-17 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US7214376B2 (en) 1991-03-18 2007-05-08 New York University Methods of inhibiting TNFα in patients with neoplastic disease
EP0610201A4 (en) * 1991-03-18 1995-05-24 Univ New York Monoclonal and chimeric antibodies specific for human tumor necrosis factor.
US7160995B2 (en) 1991-03-18 2007-01-09 New York University DNA encoding anti-TNF antibodies and peptides
US7227003B2 (en) 1991-03-18 2007-06-05 New York University Anti-TNF antibody fragments
US7252823B2 (en) 1991-03-18 2007-08-07 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7276239B2 (en) 1991-03-18 2007-10-02 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
EP1857553A1 (en) * 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
EP1857554A1 (en) * 1991-03-18 2007-11-21 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
EP1905782A1 (en) * 1991-03-18 2008-04-02 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US7374761B2 (en) 1991-03-18 2008-05-20 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7416729B2 (en) 1991-03-18 2008-08-26 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
EP0585705A1 (en) * 1992-08-28 1994-03-09 Bayer Corporation Use of anti-TNF to treat bacterial meningitis
US7250165B2 (en) 2000-08-07 2007-07-31 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US9828424B2 (en) 2000-08-07 2017-11-28 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US7691378B2 (en) 2000-08-07 2010-04-06 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7521206B2 (en) 2000-08-07 2009-04-21 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8241899B2 (en) 2000-08-07 2012-08-14 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8603778B2 (en) 2000-08-07 2013-12-10 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US9321836B2 (en) 2000-08-07 2016-04-26 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and uses
US7820169B2 (en) 2000-08-07 2010-10-26 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US8617894B2 (en) 2008-10-31 2013-12-31 Janssen Biotech, Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US11124565B2 (en) 2016-02-05 2021-09-21 Janssen Biotech, Inc. Method for treating pre-type 1 diabetes in a human subject
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Also Published As

Publication number Publication date
JP2638652B2 (en) 1997-08-06
NO901247D0 (en) 1990-03-16
ATE173766T1 (en) 1998-12-15
JPH03501330A (en) 1991-03-28
ES2124209T3 (en) 1999-02-01
DE68928857T2 (en) 1999-08-05
IL90990A (en) 1994-10-21
AU626572B2 (en) 1992-08-06
NZ229922A (en) 1992-04-28
NO901247L (en) 1990-03-16
FI101937B1 (en) 1998-09-30
PT91201A (en) 1990-02-08
EP0351789A3 (en) 1990-08-01
DK69890A (en) 1990-05-15
CA1340018C (en) 1998-09-01
FI901344A0 (en) 1990-03-16
NO179615C (en) 1996-11-13
EP0351789B1 (en) 1998-11-25
NO179615B (en) 1996-08-05
FI101937B (en) 1998-09-30
US5658803A (en) 1997-08-19
AU3970389A (en) 1990-02-19
DK69890D0 (en) 1990-03-16
DE68928857D1 (en) 1999-01-07
PT91201B (en) 1996-12-31
ZA895372B (en) 1990-04-25
IL90990A0 (en) 1990-02-09
EP0351789A2 (en) 1990-01-24

Similar Documents

Publication Publication Date Title
US5658803A (en) Monoclonal antibodies reactive with cachectin
US5639455A (en) Immunosuppressant
AU631545B2 (en) Il-2 receptor-specific chimeric antibodies
JPH0655759B2 (en) Hybrid interface and method for producing the same
NZ534269A (en) Antibodies to human IL-1beta
CN103079586A (en) Use of G-CSF dimer in the treatment of neutropenia
US20100254941A1 (en) Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
Bonventre et al. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo
AU2011268229B2 (en) Arthritis treatment
WO1991008774A1 (en) Cytokine antibody for the treatment of sepsis
EP0504307B1 (en) Method of treating septic shock
AU5309386A (en) Anti-pseudomonas aeruginosa human monoclonal antibody
JP4044733B2 (en) Humanized antibody recognizing verotoxin II and cell line producing the antibody
CN114127108A (en) Methods of treating autoimmune diseases with IL-17 antagonists
WO1991008754A1 (en) Medicinal application of m-csf
JPWO2020025703A5 (en)
NO180637B (en) Process for producing monoclonal antibodies or fragments thereof
FI102115B (en) Monoclonal antibody composition to be used as diagnostic reagent
TW202241505A (en) Method for treating autoimmune diseases and inflammation with an anti-il-17 antibody
AU2015203524A1 (en) Arthritis treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP NO

WWE Wipo information: entry into national phase

Ref document number: 901344

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 954230

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 901344

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 954230

Country of ref document: FI